Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

NCT02690948 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Skin Basal Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Vismodegib

Sponsor

Anne Chang

Collaborators

[object Object]
[object Object]